The Carlyle Group, a global asset manager, has entered an agreement to acquire Johnson & Johnson’s Ortho-Clinical Diagnostics (OCD) business for approximately $4.2 billion. OCD provides solutions for screening, diagnosing, monitoring and confirming diseases, to clinical labs and the transfusion medicine community globally. OCD operates in 130 countries and is headquartered in Raritan, NJ, with manufacturing operations in Rochester, NY, Pompano Beach, FL and Pencoed, Wales. The transaction, subject to customary regulatory approvals, is expected to close mid-2014.
 
Stephen H. Wise, Managing Director of The Carlyle Group, said, “Ortho-Clinical Diagnostics is an established global brand with a reputation for quality and innovation. Through accelerated investment in research and product development and continued expansion into both emerging and established markets, we expect to tap into rising demand for sophisticated medical diagnostic products and services worldwide. We have been focused on the diagnostics industry for many years given its attractive growth prospects, driven by the crucial role it plays in health care decision-making and influencing patient outcomes. We believe that OCD, with its world class employee base and talented management team, is poised for the next level of success.”
 
Eric Compton, worldwide president, Ortho-Clinical Diagnostics, said, “We are excited to work with Carlyle and believe OCD will be well-positioned as an independent company focused exclusively on the in vitro diagnostics market. In combination with Carlyle’s global reach and deep experience in the healthcare sector, OCD will have the opportunity to invest in new, innovative products and services for its customers and provide an environment for its professionals to excel in a competitive global marketplace.”
 
Barclays and Goldman Sachs are acting as financial advisors to The Carlyle Group and Latham & Watkins LLP is acting as legal advisor.